Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in Clostridium difficile Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab

BACKGROUND: Bezlotoxumab (BEZ) and actoxumab (ACT) are monoclonal antibodies against C. difficile toxins B and A, respectively. Patients receiving a single infusion of BEZ alone or with ACT in the MODIFY I/II trials showed a consistent reduction in the rate of rCDI over a 12-week period compared wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, Peter, Shen, Judong, Dorr, Mary Beth, Wilcox, Mark, Li, Junhua, Mogg, Robin, Mehrotra, Devan V, Blanchard, Rebecca L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631269/
http://dx.doi.org/10.1093/ofid/ofx163.941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631269/
http://dx.doi.org/10.1093/ofid/ofx163.941

Ejemplares similares